What to Expect With Medullary Thyroid Cancer (MTC) End-of-Life Care
By CRYSTAL BAI •
The short answer: Medullary thyroid cancer (MTC) is a rare cancer arising from the parafollicular C cells of the thyroid that secrete calcitonin. Advanced MTC requires specialized palliative care managing hormonal symptoms, bone and liver metastases, diarrhea from calcitonin and CEA secretion, and supporting patients through a disease that may have a prolonged but ultimately progressive course.
What to Expect With Medullary Thyroid Cancer (MTC) End-of-Life Care
Medullary thyroid cancer accounts for approximately 3-4% of all thyroid cancers but is responsible for a higher proportion of thyroid cancer deaths. It arises from parafollicular C cells (not from follicular cells like papillary or follicular thyroid cancer) and is biologically distinct. Surgical resection is the only curative treatment; distant metastatic MTC has limited treatment options.
Understanding MTC and Its Genetics
Approximately 25% of MTC is hereditary — associated with MEN2A and MEN2B syndromes and RET proto-oncogene mutations. Genetic testing of the patient and family is important for identifying relatives at risk. Sporadic MTC (the other 75%) is not hereditary.
Targeted therapies (vandetanib, cabozantinib) are FDA-approved for progressive MTC and can provide disease stability for extended periods. When these fail, the transition to palliative care is appropriate.
Calcitonin and Diarrhea
High calcitonin levels from MTC cause chronic watery diarrhea in some patients — one of the most quality-of-life-impairing symptoms. Managing diarrhea with antidiarrheal agents (loperamide, octreotide, cholestyramine) significantly improves daily functioning. As disease progresses, diarrhea severity may worsen.
Key Metastatic Sites and Their Management
Liver metastases: Pain from hepatomegaly, nausea; managed with opioids and anti-nausea medications. Palliative liver-directed therapy may be appropriate in select cases.
Bone metastases: Pain requiring opioids and palliative radiation to symptomatic sites. Pathological fracture risk requires evaluation of load-bearing bones.
Lung metastases: Dyspnea managed with opioids, positioning, and supplemental oxygen.
Paraneoplastic effects: Some MTC secretes ACTH, causing Cushing syndrome (weight gain, diabetes, psychiatric effects). Managing these effects improves quality of life.
Prolonged Disease Course
Like many endocrine cancers, MTC often follows a prolonged course. Patients may have stable metastatic disease on targeted therapy for 3-7+ years before progression. This extended trajectory requires both long-term symptom management and attention to quality of life over years, not just end of life.
Hereditary MTC and Family Implications
For hereditary MTC families (MEN2A/2B, RET mutations), end of life includes the specific grief of a heritable condition. Family members who carry the mutation may face preventive surgery decisions. Genetic counselors provide essential support for these family conversations.
Frequently Asked Questions
What is medullary thyroid cancer?
Medullary thyroid cancer (MTC) is a rare thyroid cancer arising from the parafollicular C cells, which produce calcitonin. It accounts for 3-4% of thyroid cancers but is biologically distinct from common papillary or follicular thyroid cancer. It does not respond to radioactive iodine (which only works for follicular-derived thyroid cancer). About 25% of MTC is hereditary, caused by RET proto-oncogene mutations.
Why does MTC cause diarrhea?
Medullary thyroid cancer cells secrete calcitonin and other peptides that stimulate intestinal fluid and electrolyte secretion, causing chronic watery diarrhea. Some patients also have MTC that secretes prostaglandins and other vasoactive substances contributing to diarrhea. This is often one of the most impairing symptoms of advanced MTC and requires active management with antidiarrheal medications.
What targeted therapies are used for MTC?
Two targeted therapies are FDA-approved for progressive MTC: vandetanib (Caprelsa), which targets RET, VEGFR, and EGFR pathways; and cabozantinib (Cometriq), which targets RET, VEGFR, and MET pathways. Both can provide disease stabilization and improved progression-free survival. Selpercatinib (Retevmo) is highly effective for RET-mutated MTC. When these fail, clinical trials are the next option.
Is MTC hereditary?
Approximately 25% of MTC is hereditary, caused by mutations in the RET proto-oncogene. Hereditary MTC occurs in the context of MEN2A (multiple endocrine neoplasia type 2A, which also includes parathyroid hyperplasia and pheochromocytoma) and MEN2B (which also includes marfanoid habitus, mucosal neuromas, and pheochromocytoma). Genetic testing is recommended for all MTC patients to identify hereditary cases and screen at-risk family members.
When should hospice be considered for medullary thyroid cancer?
Hospice is appropriate for MTC when targeted therapies have failed, when performance status has significantly declined, when the burden of treatment outweighs potential benefit, or when goals of care prioritize comfort over extending survival. MTC's often prolonged course means early palliative care integration alongside active treatment is valuable — not waiting until crisis to involve palliative care.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.